- European Medicines Agency's advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd's MYOV Ryeqo (relugolix, estradiol, and norethindrone acetate) for uterine fibroids.
- The final decision on the application is expected to be available in approximately two months.
- Gedeon Richter will commercialize Ryeqo for uterine fibroids, if approved, in Europe under an agreement announced in March 2020.
- Relugolix combination tablet for uterine fibroids is also under review by the FDA with a target action date of June 1.
- Price Action: MYOV shares are up 2.56% at $22.81 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
